Antibody-Radionuclide Conjugates for Solid Tumors: Multidimensional Strategies from Component Engineering to Synergistic Combination Therapy
Antibody-radionuclide conjugates (ARCs), defined as systems in which antibodies or their derivatives are linked to therapeutic or diagnostic radionuclides via covalent or non-covalent strategies, represent a promising platform for precision tumor theranostics. Their clinical application in solid tumors, however, remain...